Donald M. O'Rourke, M.D.
John Templeton, Jr., M.D. Professor in Neurosurgery
Faculty , Abramson Family Cancer Center, Cell and Development Biology Program, Cancer Biology Program, Translational Studies Program, University of Pennsylvania
Founding Member, Center for Cancer Pharmacology, University of Pennsylvania
Director, Human Brain Tumor Tissue Bank, University of Pennsylvania
Faculty Member, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania
Full Member, Institute for Translational Medicine and Therapeutics (ITMAT), University of Pennsylvania
Founding Member, Philadelphia Coalition for a Cure (PC4C), The Children's Hospital of Philadelphia, University of Pennsylvania
Mack Technology Fellow, Mack Institute for Innovation Management, The Wharton School, University of Pennsylvania, University of Pennsylvania
Director, Glioblastoma Translational Center of Excellence, Abramson Cancer Center
Faculty, Penn Center for Cellular Immunotherapies
Department: Neurosurgery
Graduate Group Affiliations
Contact information
HUP - 15th floor, South Perelman
3401 Civic Center Boulevard
Philadelphia, PA 19104
3401 Civic Center Boulevard
Philadelphia, PA 19104
Office: 215-662-3490
Fax: 215-349-5534
Fax: 215-349-5534
Publications
Education:
A.B. (Biochemistry and Molecular Biology)
Harvard University (Magna Cum Laude), 1983.
M.D. (Medicine)
University of Pennsylvania, 1987.
M.A. (Arts)
University of Pennsylvania, 2002.
Permanent linkA.B. (Biochemistry and Molecular Biology)
Harvard University (Magna Cum Laude), 1983.
M.D. (Medicine)
University of Pennsylvania, 1987.
M.A. (Arts)
University of Pennsylvania, 2002.
Selected Publications
Yin Y, Rodriguez JL, Li N, Thokala R, Nasrallah MP, Hu L, Zhang L, Zhang JV, Logun MT, Kainth D, Haddad L, Zhao Y, Wu T, Johns EX, Long Y, Liang H, Qi J, Zhang X, Binder ZA, Lin Z, O'Rourke DM: Locally secreted BiTEs complement CAR T cells by enhancing killing of antigen heterogeneous solid tumors. Mol. Ther. Page: S1525-0016(22)00309-4, May 2022.Alanio C, Binder ZA, Chang RB, Nasrallah MP, Delman D, Li JH, Tang OY, Zhang LY, Zhang JV, Wherry EJ, O'Rourke DM, Beatty GL.: Immunological features in de novo and recurrent glioblastoma associate with survival outcomes. Cancer Immunol Res. Page: canimm.CIR-21-1050-E.2021, May 2022.
Fathi Kazerooni A, Saxena S, Toorens E, Tu D, Bashyam V, Akbari H, Mamourian E, Sako C, Koumenis C, Verginadis I, Verma R, Shinohara RT, Desai AS, Lustig RA, Brem S, Mohan S, Bagley SJ, Ganguly T, O'Rourke DM, Bakas S, Nasrallah MP, Davatzikos C: Clinical measures, radiomics, and genomics offer synergistic value in AI-based prediction of overall survival in patients with glioblastoma. Sci Rep. 12(1): 8784, May 2022.
Reed-Guy L, Desai AS, Phillips RE, Croteau D, Albright K, O'Neill M, Brem S, O'Rourke DM, Amankulor NM, Bagley SJ: Risk of intracranial hemorrhage with direct oral anticoagulants versus low molecular weight heparin in glioblastoma: A retrospective cohort study. Neuro Oncol. Page: noac125, May 2022.
Tang OY, Tian L, Yoder T, Xu R, Kulikovskaya I, Gupta M, Melenhorst JJ, Lacey SF, O'Rourke DM*, Binder ZA*: PD1 Expression in EGFRvIII-Directed CAR T Cell Infusion Product for Glioblastoma Is Associated with Clinical Response. Front. Immunol. 13: 872756, May 2022.
Durgin JS, Thokala R, Johnson L, Song E, Leferovich J, Bhoj V, Ghassemi S, Milone M, Binder Z, O'Rourke DM, O'Connor RS: Enhancing CAR T function with the engineered secretion of C. perfringens neuraminidase. Mol. Ther. 30(3): 1201-1214, March 2022 Notes: Epub 2021 Nov 20.
Nazem A, Guiry SC, Pourfathi M, Ware JB, Anderson H, Iyer SK, Moon BF, Fan Y, Witschey WR, Rizi R, Bagley SJ, Desai A, O'Rourke DM, Brem S, Nasrallah M, Nabavizadeh A.: MR susceptibility imaging for detection of tumor-associated macrophages in glioblastoma. J Neurooncol. 156(3): 645-653. Feb 2022 Notes: Epub 2022 Jan 19.
R Thokala, ZA Binder, Y Yin, L Zhang, JV Zhang, DY Zhang, MC Milone, Ming GL, Song H, DM O'Rourke: High Affinity Chimeric Antigen Receptor with Cross-Reactive scFv to Clinically Relevant EGFR Oncogenic Isoforms. Front Oncol 11: 664236, Sept 2021.
Akbari H, Kazerooni AF, Ware JB, Mamourian E, Anderson H, Guiry S, Sako C, Raymond C, Yao J, Brem S, O'Rourke DM, Desai AS, Bagley SJ, Ellingson BM, Davatzikos C, Nabavizadeh A: Quantification of tumor microenvironment acidity in glioblastoma using principal component analysis of dynamic susceptibility contrast enhanced MR imaging. Sci Rep. 11(1), July 2021.
Durgin JS, Henderson F Jr, Nasrallah MP, Mohan S, Wang S, Lacey SF, Melenhorst JJ, Desai AS, Lee JYK, Maus MV, June CH, Brem S, O'Connor RS, Binder Z, O'Rourke DM: Case Report: Prolonged Survival Following EGFRvIII CAR T Cell Treatment for Recurrent Glioblastoma. Front Oncol 7(11): 669071, May 2021 Notes: eCollection 2021.